For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and the formulated version represents a true advancement . These novel therapies protect the transthyretin protein, preventing its destructive build-up and lessening the burden of the illness. Individuals are now seeing improve